Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN
8416cov_2.gif

April 17, 2006 Cover

Volume 84, Issue 16

Long the target of skepticism, oligonucleotide-based antisense drugs are starting to regain favor with investors

Full Article
Volume 84 | Issue 16

All Issues

Business

Back In The Game

Long the target of skepticism, oligonucleotide-based antisense drugs are starting to regain favor with investors

  • Graphene Eyed As The Next Big Thing In Carbon-Based Electronics

  • Chemical Stocks Star In Quarter

    Chemicals beat major indexes, while biotech and pharmaceutical shares lag behind

  • Nanotechnology In Food And Agriculture

    Database finds diverse themes and predominantly basic research in federally funded R&D

ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT